Absci announces proposed public offering of common stock

Vancouver, wash., july 24, 2025 (globe newswire) -- absci corporation (nasdaq: absi) (“absci”), a clinical-stage biopharmaceutical company advancing potential breakthrough therapeutics designed with generative ai, announced today that it has commenced an underwritten public offering of $50 million of shares of its common stock. absci also intends to grant the underwriters a 30-day option to purchase up to an additional $7.5 million of shares of its common stock. all of the shares in the proposed offering are to be sold by absci.
ABSI Ratings Summary
ABSI Quant Ranking